TechNavio's analysts forecast the Global Pulmonary Drug Delivery Systems market to grow at a CAGR of 14.47 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing incidence of lung-related or respiratory diseases. The Global Pulmonary Drug Delivery Systems market has also been witnessing an increasing adoption of online marketing strategy. However, intense competition among vendors could pose a challenge to the growth of this market.
TechNavio's report, the Global Pulmonary Drug Delivery Systems Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the APAC and EMEA regions; it also covers the Global Pulmonary Drug Delivery Systems market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this space 3M Healthcare Ltd., AstraZeneca plc, GlaxoSmithKline plc, and Sunovion Pharmaceuticals Inc.
The other vendors mentioned in this report are Akela Pharma Inc., Alkermes Inc., Allied Healthcare Products Inc., Boehringer Ingelheim GmbH, CareFusion Corp., Chiesi Farmaceutici S.p.A., Dainippon Sumitomo Pharma Co. Ltd., GF Health Products Inc., Novartis AG, PARI Respiratory Equipment Inc., Philips Respironics Inc., Omron Healthcare Co. Ltd., SkyePharma plc, and Vectura Group plc.
Key questions answered in this report:
What will the market size be in 2016 and at what will be the growth rate?
What are key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details provided within the report.